# A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia

> **NCT00915512** · PHASE4 · COMPLETED · sponsor: **Janssen-Cilag Turkey** · enrollment: 84 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Paliperidone extended-release (ER)

## Key facts

- **NCT ID:** NCT00915512
- **Lead sponsor:** Janssen-Cilag Turkey
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2013-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00915512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00915512, "A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00915512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*